278 related articles for article (PubMed ID: 17956715)
1. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
Gulley JL; Wu S; Arlen PM; Dahut WL
Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
Patel K; Brahmbhatt V; Ramu V
Tenn Med; 2005 Feb; 98(2):83-5, 89. PubMed ID: 15779196
[TBL] [Abstract][Full Text] [Related]
3. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?
Ho JW; Sundar S
Clin Genitourin Cancer; 2012 Mar; 10(1):50-3. PubMed ID: 22245101
[No Abstract] [Full Text] [Related]
4. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
5. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
6. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
Mishra A
J Postgrad Med; 2008; 54(3):237. PubMed ID: 18626181
[No Abstract] [Full Text] [Related]
7. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
8. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
Zuradelli M; Masci G; Biancofiore G; Gullo G; Scorsetti M; Navarria P; Tancioni F; Berlusconi M; Giordano L; Santoro A
Oncologist; 2009 May; 14(5):548-56. PubMed ID: 19411682
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Michaelson MD; Kaufman DS; Kantoff P; Oh WK; Smith MR
Cancer; 2006 Aug; 107(3):530-5. PubMed ID: 16804927
[TBL] [Abstract][Full Text] [Related]
10. [Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].
Paparella S; Finkelberg E; Varisco D; Tondelli E; Rocco F
Urologia; 2011; 78(4):300-4. PubMed ID: 22139807
[TBL] [Abstract][Full Text] [Related]
11. Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor.
Hanamura M; Iwamoto T; Soga N; Sugimura Y; Okuda M
Biol Pharm Bull; 2010; 33(4):721-4. PubMed ID: 20410614
[TBL] [Abstract][Full Text] [Related]
12. Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
Joensuu TK
Urol Int; 2008; 80(4):448-50. PubMed ID: 18587260
[TBL] [Abstract][Full Text] [Related]
13. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
14. Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.
Milat F; Goh S; Gani LU; Suriadi C; Gillespie MT; Fuller PJ; Teede HJ; Strickland AH; Allan CA
Bone; 2013 Aug; 55(2):305-8. PubMed ID: 23685544
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid treatment at home: safety data from an observational prospective trial.
Tassinari D; Poggi B; Nicoletti S; Fantini M; Tamburini E; Possenti C; Sartori S
J Palliat Med; 2007 Apr; 10(2):352-8. PubMed ID: 17472506
[TBL] [Abstract][Full Text] [Related]
17. Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases.
Serefoglu EC; Balbay MD
Med Hypotheses; 2009 Sep; 73(3):387-8. PubMed ID: 19403241
[TBL] [Abstract][Full Text] [Related]
18. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.
Olson KB; Hellie CM; Pienta KJ
Urology; 2005 Sep; 66(3):658. PubMed ID: 16140106
[TBL] [Abstract][Full Text] [Related]
20. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
